Anzeige
Mehr »
Montag, 08.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QR9 | ISIN: FR0012616852 | Ticker-Symbol: 609
Frankfurt
05.09.25 | 08:02
3,720 Euro
+7,36 % +0,255
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ABIONYX PHARMA SA Chart 1 Jahr
5-Tage-Chart
ABIONYX PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,5753,71007.09.
3,6253,73005.09.

Aktuelle News zur ABIONYX PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital194Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
28.08.ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025387Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's...
► Artikel lesen
27.08.ABIONYX Pharma Announces the Start of Discussions With a Major Player in the Field of Sepsis for a Strategic Partnership343Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's...
► Artikel lesen
21.08.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital313Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX) Market:...
► Artikel lesen
04.07.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital392Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX) Market:...
► Artikel lesen
03.07.ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract With TP ICAP (Europe) SA346Regulatory News: Under the liquidity contract entered into by ABIONYX Pharma (Paris:ABNX) with TP ICAP (Europe) SA, the following assets were included in the liquidity account at June 30, 2025:...
► Artikel lesen
ABIONYX PHARMA Aktie jetzt für 0€ handeln
27.06.ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting335Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's...
► Artikel lesen
03.06.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital317Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX) Market:...
► Artikel lesen
28.05.ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2025390Consolidated sales of 1 M€ at end March 2025 Cash position of 4.1 M€ at March 31, 2025 before collection of Research Tax Credit of 1.08 M€ Anticipated key milestone: feedback from...
► Artikel lesen
06.05.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital280Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
03.04.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital378Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
21.03.CIC Market Solutions Initiates Buy Coverage of ABIONYX Pharma358Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), next-generation biopharma dedicated to the development of innovative biomedicines based on recombinant apolipoprotein apoA-I...
► Artikel lesen
17.03.ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2024253Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein...
► Artikel lesen
05.03.ABIONYX Pharma Announces Its 2024 Full-Year Results342Improved profitability of IRIS Pharma with a net income of 6% of revenues Extended financial visibility to the 2nd quarter of 2026 after the support of the France 2030 plan Regulatory...
► Artikel lesen
04.03.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital303Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
28.02.ABIONYX Pharma: World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances310Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis Preparation for the submission of the Marketing Authorization Application...
► Artikel lesen
28.02.ABIONYX Pharma: World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances335Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis Preparation for the submission of the Marketing Authorization Application...
► Artikel lesen
27.02.ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2024620Consolidated revenue of €4.6m in 2024 Available cash of €3.2m at December 31, 2024 Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX eligible for PEA PME), a next generation biopharma...
► Artikel lesen
20.02.ABIONYX Pharma, winner of the France 2030 Plan's "i-Démo" call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide450ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant...
► Artikel lesen
10.02.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital239Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1